Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 2
2012 6
2013 8
2014 2
2015 8
2016 10
2017 14
2018 6
2019 2
2020 5
2021 2
2022 1
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL.
Xu-Monette ZY, Li Y, Snyder T, Yu T, Lu T, Tzankov A, Visco C, Bhagat G, Qian W, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Wang Y, Go H, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Fan X, van Krieken JH, Piris MA, Winter JN, Au Q, Kirsch I, Zhang M, Shaughnessy J, Xu B, Young KH. Xu-Monette ZY, et al. Clin Cancer Res. 2023 Dec 1;29(23):4808-4821. doi: 10.1158/1078-0432.CCR-23-1554. Clin Cancer Res. 2023. PMID: 37728879
Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma.
Sircar A, Singh S, Xu-Monette ZY, Coyle KM, Hilton LK, Chavdoula E, Ranganathan P, Jain N, Hanel W, Tsichlis P, Alinari L, Peterson BR, Tao J, Muthusamy N, Baiocchi R, Epperla N, Young KH, Morin R, Sehgal L. Sircar A, et al. Leukemia. 2023 Oct;37(10):2094-2106. doi: 10.1038/s41375-023-02006-8. Epub 2023 Aug 19. Leukemia. 2023. PMID: 37598282 Free PMC article.
EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential.
Li Y, Xu-Monette ZY, Abramson J, Sohani AR, Bhagat G, Tzankov A, Visco C, Zhang S, Dybkaer K, Pan Z, Xu M, Tam W, Zu Y, Hsi ED, Hagemeister FB, Go H, van Krieken JH, Winter JN, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Wang Y, Zhang M, Young KH. Li Y, et al. Blood Adv. 2023 Apr 11;7(7):1308-1311. doi: 10.1182/bloodadvances.2022008550. Blood Adv. 2023. PMID: 36399513 Free PMC article. No abstract available.
Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma.
Xu-Monette ZY, Wei L, Fang X, Au Q, Nunns H, Nagy M, Tzankov A, Zhu F, Visco C, Bhagat G, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Sun X, Han X, Go H, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, van Krieken JH, Piris MA, Winter JN, Li Y, Xu B, Albitar M, You H, Young KH. Xu-Monette ZY, et al. Clin Cancer Res. 2022 Mar 1;28(5):972-983. doi: 10.1158/1078-0432.CCR-21-2949. Clin Cancer Res. 2022. PMID: 34980601 Free PMC article.
Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.
Deng M, Xu-Monette ZY, Pham LV, Wang X, Tzankov A, Fang X, Zhu F, Visco C, Bhagat G, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, You H, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Hagemeister F, van Krieken JH, Piris MA, Winter JN, Li Y, Xu B, Liu P, Young KH. Deng M, et al. Mol Cancer Res. 2021 Feb;19(2):249-260. doi: 10.1158/1541-7786.MCR-20-0466. Epub 2020 Nov 5. Mol Cancer Res. 2021. PMID: 33154093 Free PMC article.
Therapeutic vaccines for aggressive B-cell lymphoma.
Xu-Monette ZY, Young KH. Xu-Monette ZY, et al. Leuk Lymphoma. 2020 Dec;61(13):3038-3051. doi: 10.1080/10428194.2020.1805113. Epub 2020 Aug 25. Leuk Lymphoma. 2020. PMID: 32840404 Free PMC article.
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL.
Xu-Monette ZY, Zhang H, Zhu F, Tzankov A, Bhagat G, Visco C, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, You H, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, van Krieken JH, Piris MA, Winter JN, Hagemeister FB, Shahbaba B, De Dios I, Zhang H, Li Y, Xu B, Albitar M, Young KH. Xu-Monette ZY, et al. Blood Adv. 2020 Jul 28;4(14):3391-3404. doi: 10.1182/bloodadvances.2020001949. Blood Adv. 2020. PMID: 32722783 Free PMC article.
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.
Xu-Monette ZY, Li J, Xia Y, Crossley B, Bremel RD, Miao Y, Xiao M, Snyder T, Manyam GC, Tan X, Zhang H, Visco C, Tzankov A, Dybkaer K, Bhagat G, Tam W, You H, Hsi ED, van Krieken JH, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Winter JN, Medeiros JT, Xu B, Li Y, Kirsch I, Young KH. Xu-Monette ZY, et al. J Immunother Cancer. 2019 Oct 22;7(1):272. doi: 10.1186/s40425-019-0730-x. J Immunother Cancer. 2019. PMID: 31640780 Free PMC article.
57 results